MP63-18 UriFIND ASSAY FACILITATES WHOLE COURSE MANAGEMENT OF UROTHELIAL CARCINOMA IN A LARGE MULTICENTRIC, PROSPECTIVE CHINA COHORT
Chen Xu,Zheng Liu,Liqun Zhou,Jinhai Fan,Weimei Ruan,Hong Wang,Qiang Lu,Qiang Wei,Haige Chen,Tao Xu,Lei Li,Shaogang Wang,Wanglong Tan,Abai Xu,Yang Jin,Hong Liao,Jianmei Zhong,Xia Li,Zhiwei Chen,Marina Bibikova,Jian‐Bing Fan,Jian Huang,Tianxin Lin
DOI: https://doi.org/10.1097/ju.0000000000003321.18
IF: 7.6
2023-01-01
The Journal of Urology
Abstract:You have accessJournal of UrologyCME1 Apr 2023MP63-18 UriFIND ASSAY FACILITATES WHOLE COURSE MANAGEMENT OF UROTHELIAL CARCINOMA IN A LARGE MULTICENTRIC, PROSPECTIVE CHINA COHORT XU Chen, Zheng Liu, Liqun Zhou, Jinhai Fan, Weimei Ruan, Hong Wang, Qiang Lv, Qiang Wei, Haige Chen, Tao Xu, Lei Li, Shaogang Wang, Wanglong Tan, Abai Xu, Jin Yang, Hong Liao, Jianmei Zhong, Xia Li, Zhiwei Chen, Marina Bibikova, Jianbing Fan, Jian Huang, and Tianxin Lin XU ChenXU Chen More articles by this author , Zheng LiuZheng Liu More articles by this author , Liqun ZhouLiqun Zhou More articles by this author , Jinhai FanJinhai Fan More articles by this author , Weimei RuanWeimei Ruan More articles by this author , Hong WangHong Wang More articles by this author , Qiang LvQiang Lv More articles by this author , Qiang WeiQiang Wei More articles by this author , Haige ChenHaige Chen More articles by this author , Tao XuTao Xu More articles by this author , Lei LiLei Li More articles by this author , Shaogang WangShaogang Wang More articles by this author , Wanglong TanWanglong Tan More articles by this author , Abai XuAbai Xu More articles by this author , Jin YangJin Yang More articles by this author , Hong LiaoHong Liao More articles by this author , Jianmei ZhongJianmei Zhong More articles by this author , Xia LiXia Li More articles by this author , Zhiwei ChenZhiwei Chen More articles by this author , Marina BibikovaMarina Bibikova More articles by this author , Jianbing FanJianbing Fan More articles by this author , Jian HuangJian Huang More articles by this author , and Tianxin LinTianxin Lin More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003321.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The gold standard to diagnose and monitor urothelial carcinoma is cystoscopy, which is invasive and painful. The currently available non-invasive methods to detect urothelial carcinoma are either of unsatisfying sensitivity or limited specificity in China. Previously, a DNA methylation assay, termed UriFind®, was developed, and showed a compelling sensitivity and specificity in a retrospective cohort. This study aimed to further validate its performance in a large multicentric, prospective China cohort. METHODS: Patients involved in the whole course of UC management were recruited in this cohort. The cohort contained 931 patients diagnosed with urothelial carcinoma (UC), and 994 controls with benign diseases and 78 healthy participants from 12 hospitals across China. Urine samples were collected before the therapy, and analyzed with quantitative PCR of ONECUT2 and VIM methylation (UriFind®), FISH and urinary cytology. Sensitivity, specificity, accuracy, PPV and NPV of these assays were evaluated as compared to the diagnostic gold standard of cystoscopy, histology results or clinical diagnosis. RESULTS: The UC group of the cohort consisted of 683 non-muscle invasive UC (73.4%), 203 muscle invasive UC (21.8%) and 45 unavailable stage (4.8%). The patients of low, high-grade UC and unavailable grade were 244(26.2%), 651(69.9%) and 36 (3.9%), respectively. Overall sensitivity, specificity, accuracy, PPV and NPV of UriFind® was 82.3%, 91.2%, 87.3%, 88.1% and 86.7%, respectively. The specificity of healthy participants was 100%. The overall sensitivity and accuracy of UriFind® were significantly higher than urine cytology (40% and 55.7%) and FISH (68.2% and 73.6%), while the specificity was similar to cytology (93.9%) and FISH (87.3%). Importantly, UriFind® achieved a great improvement of sensitivity in whole course management, including low grade tumor (56.1%), small and single tumor (63.3%), residual tumor after therapy (71.4%) and recurrent tumor (84.3%). CONCLUSIONS: The performance of UriFind® is well validated with significantly higher sensitivity and accuracy than urine cytology and FISH in UC detection in this cohort with 2003 cases. This assay facilitates whole course management of urothelial carcinoma, which may reduce the burden of cystoscopy and unnecessary second TURBT. Source of Funding: This study was supported by the National Key Research and Development Program of China (Grant No. 2022YFC2408300) © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e878 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information XU Chen More articles by this author Zheng Liu More articles by this author Liqun Zhou More articles by this author Jinhai Fan More articles by this author Weimei Ruan More articles by this author Hong Wang More articles by this author Qiang Lv More articles by this author Qiang Wei More articles by this author Haige Chen More articles by this author Tao Xu More articles by this author Lei Li More articles by this author Shaogang Wang More articles by this author Wanglong Tan More articles by this author Abai Xu More articles by this author Jin Yang More articles by this author Hong Liao More articles by this author Jianmei Zhong More articles by this author Xia Li More articles by this author Zhiwei Chen More articles by this author Marina Bibikova More articles by this author Jianbing Fan More articles by this author Jian Huang More articles by this author Tianxin Lin More articles by this author Expand All Advertisement PDF downloadLoading ...